Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
plans to open a new office in London’s vibrant King’s Cross
neighborhood. Set to formally open in June 2024, the site will
provide Recursion and Valence Labs, the company’s artificial
intelligence research engine, access to world-class talent across
Europe’s rapidly growing TechBio sector and embed Recursion in a
thriving innovation ecosystem of leading technology and life
science companies.
"As Recursion continues to lead and define the TechBio industry,
it's critical we hire the best possible talent, much of which is
located in Europe," said Chris Gibson, Ph.D., Co-founder and CEO at
Recursion. "London stood out as an ideal location given its
brilliant and interdisciplinary talent across the fields of
technology, biology and chemistry. It’s also the epicenter for the
rapidly growing TechBio sector in Europe, where leading technology
and life science companies like Google and Merck both sit within
walking distance of our new Recursion site. I look forward to
expanding our operations in Europe and hiring many new
Recursionauts who will help us advance our mission of decoding
biology to radically improve lives.”
To support Recursion’s leadership in TechBio and entry into
London, the company is excited to announce the addition of Michael
Bronstein, DeepMind Professor of Artificial Intelligence at Oxford
University, as a Scientific Advisor. Professor Bronstein is a world
leader in geometric deep learning, graph neural networks, and
protein design. Professor Bronstein joins AI luminary Professor
Yoshua Bengio in supporting Recursion and Valence Labs in the
development of state-of-the-art AI models to support the
industrialization of drug discovery.
“Recursion is leading the field in advancing cutting-edge AI
research for real-world applications with the potential to
radically improve lives, and I’m honoured to join them in their
mission,” said Prof Michael Bronstein. “I have collaborated with
Valence prior to their acquisition by Recursion, and I look forward
to continuing to work with the team to advance this important work,
especially as Recursion continues to grow in London.”
Recursion’s 6,700 square foot London office will be located at 3
Pancras Square, King’s Cross London. The building is part of a
67-acre redevelopment project in the heart of King’s Cross, with
over 4.5 million square feet of office space. Located within a
3-minute walk from King’s Cross Station and St. Pancras
International, the site offers excellent transit access. The
building includes an onsite cafe, bicycle storage, showers, prayer
room and mothers room. In line with Recursion’s commitment to
sustainability, the building meets the requirements for an
“Excellent” rating by BREEAM building standards and is linked to a
site-wide district heating and cooling network that results in
net-zero carbon emissions.
“The UK Government’s plan for attracting more inward investment
into the UK is working. Recursion’s investment is yet another vote
of confidence in the UK, our top talent and our amazing tech and
life sciences industries,” said Investment Minister Lord Johnson.
“I’m delighted Recursion has chosen London, and we’ll continue to
do everything we can to ensure the UK remains the top choice for
investments like this.”
Today, Recursion has over 500 employees with a near-equal mix of
life scientists and technologists across sites in Salt Lake City,
Toronto, Montréal, and the San Francisco Bay Area. Recursion’s new
London office will serve as an extension of both Recursion and
Valence Labs’ teams. To launch recruiting efforts for the new site,
Recursion has opened multiple new roles across technology and
biology functions with immediate plans to hire the first 20 people
to be based out of the new London office. Recursion and Valence
Labs will also host a TechBio Mixer tomorrow, March 12, at the
location of its new site to celebrate the office and network with
the TechBio community.
For more information on open positions and to apply, visit
recursion.com/careers and valencelabs.com/careers.
About RecursionRecursion is a clinical stage
TechBio company leading the space by decoding biology to
industrialize drug discovery. Enabling its mission is the Recursion
OS, a platform built across diverse technologies that continuously
expands one of the world’s largest proprietary biological, chemical
and patient-centric datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology, chemistry and patient-centric data to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Media ContactMedia@Recursion.com
Investor ContactInvestor@Recursion.com
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements'' within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, those
regarding the opening of the London office and timing of such
opening; the recruitment efforts and number of roles at the London
office; and all other statements that are not historical facts.
Forward-looking statements may or may not include identifying words
such as “plan,” “will,” “expect,” “anticipate,” “intend,”
“believe,” “potential,” “could,” “continue,” and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K for the Fiscal
Year Ended December 31, 2023. All forward-looking statements are
based on management’s current estimates, projections, and
assumptions, and Recursion undertakes no obligation to correct or
update any such statements, whether as a result of new information,
future developments, or otherwise, except to the extent required by
applicable law.
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024